Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEH1 | O60930 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | EDNRB | P24530 | 2/20 | 0.35 |
| ▸ | EDNRA | P25101 | 2/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30454412 | 1.00 | RNASEH1 (0.40) | RNASEH1ALDH1A1P2RX3KDM5AKDM4C | |
| Glycine SCHEMBL29248942 | 0.94 | RNASEH1 (0.37) | RNASEH1ALDH1A1P2RX3KDM5AKDM4C | |
| SCHEMBL30452343 | 0.89 | RNASEH1 (0.47) | RNASEH1ALDH1A1KDM4EGAAHPGD | |
| SCHEMBL24257827 | 0.89 | RNASEH1 (0.47) | RNASEH1ALDH1A1KDM4EGAAHPGD | |
| SCHEMBL24257456 | 0.85 | EGLN1 (0.48) | — | |
| Glycine SCHEMBL30546853 | 0.84 | TDP1 (0.39) | ALDH1A1KDM4EGAATDP1SMN1; SMN2 | |
| SCHEMBL24257784 | 0.82 | PPID (0.43) | ALDH1A1KDM4EGAAHPGDTDP1 | |
| SCHEMBL30452335 | 0.82 | PPID (0.43) | ALDH1A1KDM4EGAAHPGDTDP1 | |
| Formic Acid SCHEMBL30454433 | 0.82 | EGLN1 (0.45) | — | |
| SCHEMBL29248940 | 0.81 | ALDH1A1 (0.35) | ALDH1A1KDM5AKDM4CKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| CN-116670131-A | PHD inhibitor compounds, compositions, and methods of use | 阿克比治疗有限公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2022036188-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN3, PHF20 | RNASEH1 2628/4885ALDH1A1 1362/4885P2RX3 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.